A5031603815- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Pancreatitis Pathology and Treatment
- Cardiac Arrhythmias and Treatments
- Cardiac pacing and defibrillation studies
- Cardiac electrophysiology and arrhythmias
- Atrial Fibrillation Management and Outcomes
- Pharmaceutical studies and practices
- Regulation of Appetite and Obesity
- Adipose Tissue and Metabolism
- Mechanical Circulatory Support Devices
- Testicular diseases and treatments
- Clinical Nutrition and Gastroenterology
- Cardiovascular Syncope and Autonomic Disorders
- Vitamin K Research Studies
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Stress Responses and Cortisol
- Cardiac Arrest and Resuscitation
- Cardiac Ischemia and Reperfusion
Montreal Heart Institute
1996-2023
University of Aberdeen
2014
Bristol-Myers Squibb (Germany)
2014
Amplyx Pharmaceuticals (United States)
2010
St. Luke's Hospital
1996
Mayo Clinic in Florida
1996
St. Vincent's Medical Center
1996
Ganesh Shankar Vidyarthi Memorial Medical College
1975
AimDespite prompt revascularization of acute myocardial infarction (AMI), substantial injury may occur, in part a consequence ischaemia reperfusion (IRI). There has been considerable interest therapies that reduce IRI. In experimental models AMI, sodium nitrite substantially reduces this doubleblind randomized placebo controlled parallel-group trial, we investigated the effects administered immediately prior to patients with ST-elevation (STEMI).
The risk of developing pancreatitis is elevated in type 2 diabetes and obesity. Cases have been reported patients treated with GLP-1 (GLP-1R) receptor agonists. To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, effect was evaluated normal diabetic rodents. Normal rats received a single dose (0.072, 0.24, 0.72 nmol/kg) vehicle. Diabetic ob/ob HF-STZ mice were infused (1.2 7.2 nmol·kg(-1)·day(-1)) vehicle for 4 wk. Post-exenatide treatment, induced...
The potential association of glucagon-like peptide receptor agonists (GLP-1RAs) with the development pancreatitis or pancreatic malignancies in patients diabetes has been suggested. This study evaluated long-term effects GLP-1RA exenatide on exocrine structure and function Zucker diabetic fatty (ZDF) rat model type 2 diabetes.Rats received subcutaneous twice-daily injections 0 (control), 6, 40 250 µg/kg/day for 3 months. Clinical signs, body pancreas weight, food consumption, HbA1c, fasting...
Glucagon-like peptide 1-based therapies, collectively described as incretins, produce glycemic benefits in the treatment of type 2 diabetes. Recent publications raised concern for a potential increased risk pancreatitis and pancreatic cancer with incretins based part on findings from small number rodents. However, extensive toxicology assessments substantial animals dosed up to years at high multiples human exposure do not support these concerns. We hypothesized that lesions being attributed...
Recent reports in the literature have suggested that glucagon-like peptide-1 (GLP-1)-based therapies may lead to increased risk of pancreatic pathology leading chronic injury and neoplasia. Extensive non-clinical clinical safety testing was conducted support global development exenatide twice daily, once weekly saxagliptin. Our aim integrate these data obtained with both mechanisms GLP-1-based drugs provide complementary regarding potential for drug-induced signals.More than 70 regulated...
Abstract Exenatide, a glucagon‐like peptide‐1 receptor agonist was originally developed as either twice daily or once weekly injectable therapeutic for patients with type 2 diabetes. Exenatide QW suspension use an autoinjector device, in which the microspheres are suspended Miglyol 812, mixture of medium chain triglycerides (MCTs). MCTs class lipids whose fatty acid chains contain from six to 12 carbon atoms (medium acids MCFAs). While edible oils present many foods, including foodstuffs...
BACKGROUND: Despite chronic therapies, atrial fibrillation (AF) leads to rapid ventricular rates (RVR) often requiring intravenous treatments. Etripamil is a fast-acting, calcium-channel blocker administered intranasally affecting the atrioventricular node within minutes. METHODS: Reduction of Ventricular Rate in Patients with Atrial Fibrillation evaluated efficacy and safety etripamil for reduction rate (VR) patients presenting urgently AF-RVR (VR ≥110 beats per minute [bpm]), was...